Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
PR Newswire•14/11/2026•12:01 ET
2
Key Highlights
- ➤EloraTZP delivered up to 23.3% weight loss and reduced A1C by up to 2.9% at 48 weeks
- ➤Retatrutide cut sleep-apnea breathing disruptions by up to 60.6% at 80 weeks
- ➤Retatrutide reduced knee osteoarthritis pain by up to 75.8% in Phase 3 trials
- ➤Zepbound reduced adolescent BMI by 21.4%, with over half losing obesity classification
- ➤Foundayo users reported 96-98% ease and convenience in real-world survey
Expert Statements
Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health
“Obesity care is about more than numbers on the scale: it is about improving overall health and addressing the myriad of ways the disease can affect daily life, through treatment options that meet different needs. At ObesityWeek 2026, new evidence across our portfolio reflects a broader view of care, including clinical outcomes for varied populations and obesity-related conditions, as well as the treatment experience for people who take these medicines. Together, these data reinforce how Lilly has helped to transform obesity care and continues to advance next-generation treatment options.”
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale PR Newswire
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes
Get started
Create a free account to read the full story.
